https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30091 Wed 11 Apr 2018 12:04:08 AEST ]]> [Lu-177]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47980 Tue 21 Mar 2023 16:56:35 AEDT ]]> Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14865 Tue 13 Aug 2024 08:51:00 AEST ]]> Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29413 Sat 24 Mar 2018 07:36:21 AEDT ]]> Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29414 Sat 24 Mar 2018 07:36:12 AEDT ]]> Association of pembrolizumab with tumor response and survival among patients with advanced melanoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29369 Sat 24 Mar 2018 07:34:17 AEDT ]]> Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54742 Mon 11 Mar 2024 14:26:03 AEDT ]]>